Inicio › Cáncer de endometrio › Rhode Island › Providence
Ensayos clínicos de Cáncer de endometrio en Providence, RI
15 estudios para Cáncer de endometrio buscan participantes en centros de Providence y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
ReclutandoFase 3
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
ReclutandoFase 3
- Women and Infants Hospital, Providence
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ReclutandoFase 2
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ReclutandoFase 2
- Women and Infants Hospital, Providence
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
ReclutandoFase 2
- Women and Infants Hospital, Providence
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
ReclutandoFase 3
- Women & Infants Hospital ( Site 5003), Providence
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
ReclutandoFase 1
- Women & Infants Hospital of Rhode Island, Providence
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ReclutandoFase 1
- Women and Infants Hospital, Providence
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
ReclutandoFase 3
- Research Site, Providence
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
ReclutandoFase 2
- Women & Infants Hospital, Providence
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
ReclutandoFase 1/2
- Research Site, Providence
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
ReclutandoFase 1/2
- Women and Infants Hospital of Rhode Island, Providence
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
ReclutandoFase 2
- Women & Infants Hospital, Providence
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
ReclutandoFase 1/2
- Women & Infants Hospital, Providence
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Providence
Ensayos de Cáncer de endometrio en otras ciudades
- Houston, TX69 estudios
- New York City, NY53 estudios
- Boston, MA50 estudios
- Arlington, VA39 estudios
- Nashville, TN37 estudios
- Los Angeles, CA35 estudios
- St. Louis, MO29 estudios
- Philadelphia, PA29 estudios
- San Antonio, TX27 estudios
- Columbus, OH26 estudios
- Chicago, IL26 estudios
- Queens, NY26 estudios
Otros estudios en Providence
- Cáncer de ovario15 estudios
- Obesidad14 estudios
- Cáncer (todos los tipos)13 estudios
- Enfermedad de Crohn12 estudios
- Cáncer de pulmón de células no pequeñas12 estudios
- Cáncer de seno11 estudios
- Colitis ulcerativa11 estudios
- Leucemia mielógena aguda10 estudios
- Sobrepeso9 estudios
- Cáncer metastásico9 estudios
- Trastorno por consumo de alcohol8 estudios
- Enfermedad de Alzheimer8 estudios
De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.